Join the Ovarian Cancer group to help and get support from people like you.
Ovarian Cancer News (Page 3)
Related terms: Cancer, Ovarian, Cancer, Ovaries
FDA Approves Zejula (niraparib) as the Only Once-Daily PARP Inhibitor in First-Line Monotherapy Maintenance Treatment for Women with Platinum-Responsive Advanced Ovarian Cancer Regardless of Biomarker Status
London UK – 29 April 2020 -- Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Women with advanced ovarian cancer have a five-year survival rate of less than 50%. This expanded ...
FDA Approves Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
23 October 2019 – GlaxoSmithKline (LSE/NYSE: GSK) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for Zejula...
Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
19 December 2018 – AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for use as...
FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
South San Francisco, CA – June 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® ...
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 6, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) tablets for the...
FDA Approves Tablet Formulation of Lynparza (olaparib) for Maintenance Treatment of Ovarian Cancer
August 17, 2017 – AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the...
Tesaro Announces FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer
WALTHAM, MA, March 27, 2017 – Tesaro, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Zejula (...
FDA Grants Accelerated Approval to Rubraca (rucaparib) for Advanced Ovarian Cancer
December 19, 2016 – The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for...
FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
South San Francisco, CA – December 6, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Medwatch Alert: Ovarian Cancer Screening Tests: Safety Communication - FDA Recommends Against Use
ISSUE: The FDA is alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests. The Agency is especially concerned about delaying effective...
FDA Approves Lynparza (olaparib) to Treat Advanced Ovarian Cancer
December 19, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with...
FDA Approves Avastin (bevacizumab) Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer
South San Francisco, Calif. – November 14, 2014 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Avastin in combination with...
FDA Medwatch Alert: Carboplatin Injection by Hospira: Recall - Visible Particulate Matter Identified
ISSUE: Hospira, Inc. is further informing the general public about a previously communicated voluntary user-level recall of three lots of Carboplatin Injection due to visible particulates identified...